Appendix A: The Renal Registry Rationale

1. Executive summary

2. Introduction

3. Statement of intent

4. Relationships of the renal registry

5. The role of the Renal Registry for nephrologists

6. The role of the Renal Registry for trust managers

7. The role of the Renal Registry for commissioning agencies

8. The role of the Renal Registry National Quality Assurance schemes

9. The role of the Renal Registry for patients.

10. Abbreviations

11. References

A:1 Executive summary

1.1 The Renal Registry has been established by the Renal Association to act as a resource in the development of patient care in renal disease.

1.2 The Registry will act as a source of comparative data for Audit/Benchmarking, Planning, Policy and Research. The collection and analysis of sequential biochemical and haematological data will be a unique feature of the Registry.

1.3 Agreements will be made with participating renal centres which ensure a formal relationship with the Registry and safeguard confidentiality.

1.4 The essence of the Agreement will be the acceptance of the Renal Registry Data Set Specification as the basis of data transfer and retention.

1.5 Data will be collected quarterly to maintain Unit-level quality assurance, with an annual report and six monthly Unit Reports.

1.6 Ultimately activity will have to be self-funded by capitation of renal patients from commissioning agencies.

1.7 The Registry is likely, with the express agreement of participants, to become responsible for providing data to Trusts, Commissioning Authorities and Regional Offices, and the new ERA-EDTA Registry.

1.8 The development of the Registry will be open to influence from all interested parties, including Clinicians, Trusts, Commissioning Authorities and Patient Groups.

1.9 The Registry has charitable status through the Renal Association.
A:2 Introduction

2.1 Registry-based National Specialty Comparative Audit is likely to be one of the cornerstones of NHS development. “The National Renal Review” published in 1995 recommended participation of renal units in comparative audit (1). Chief Executives are now responsible for Clinical Governance and comparative audit at national level will be an essential part of this agenda, (2). The UK Renal Registry will facilitate such audit. This audit demands regular transmission of large volumes of data, which has become possible with developments in electronic data handling. The Scottish Renal Registry, established with financial support from the Scottish Office, demonstrated the practicalities of electronic data collection in a UK renal environment.

2.2 The need for careful comparative audit is likely to be confirmed through the development of Government Agencies, such as the National Institute for Clinical Excellence (NICE) and the Centre for Health Improvement (CHIMP). The final relationship of the Registry to these organisations as they develop is yet to be defined.

2.3 Demographic information on patients receiving Renal Replacement Therapy (RRT) throughout Europe was collected from 1965 in the Registry of the European Dialysis and Transplant Association (EDTA). This voluntary exercise was conducted on paper and by post, demanded considerable effort and time from participating units, and eventually proved impossible for many UK renal units. In recent years the incompleteness of UK data returns to EDTA has meant that it was not possible to build a picture of activity RRT in the UK for planning and policy purposes, although two ad hoc national data collections from England and Wales were solicited from renal centres in 1992 and 1996. The Registry will meet this need for demographic and economic data necessary for effective planning.

2.4 Together with the need to know the demographic and economic elements of the Health Service has developed a need to underpin clinical activity more rigorously through the scientific evidence base (for example the Cochrane Initiative) and by quality assurance activity through audit. These initiatives require comprehensive information about the Structures Processes and Outcomes’ of RRT, which go well beyond the detail previously compiled by EDTA.

2.5 The Registry is recognised as one of the few High Quality Clinical Databases available for general use (3).

2.6 The aspiration for renal services to be provided within a National Service Framework (NSF) is underpinned by the development of the Renal Registry (A First Class Service: Quality in the new NHS) (4). Although the Department of Health has no immediate plans for a NSF for renal services, the Renal Alliance, a group comprising patients, nephrologists and representatives of other groups involved with renal care, is in the process of developing a shadow NSF. Input from the Renal Registry will be an important feature of the Framework.

2.7 Similar cultural pressures have more recently affected all clinical disciplines, so that Registries are implemented or planned in cardiac surgery, intensive care, diabetes etc.

2.8 The Renal Association has made a start in the area of Audit by publishing guidelines in ‘Renal Standards’ documents. It was apparent during the development of the guidelines that many criteria of clinical performance were uncertain or unknown, and that only the accumulated data of practising renal units could provide the evidence for advice on best practice and what might realistically be achieved. A common data registration provides the simplest device for such comparative audit.

2.9 The recent emphasis on Evidence Based Practice is being supported by the changes in research funding (Culyer Report), which lean towards collaborative projects and include both basic science and ‘Health Services Research’ components. It is apparent that a RRT database could be invaluable to a wide range of research studies.

2.10 It can be seen that the need for a Registry of RRT has developed for a variety of reasons; international comparisons, national planning, local Trust and Health Authority management, standard setting, audit, and research. The opportunity for data gathering partly arises from improvements in information technology. While it was possible to see the need for a national renal database a decade and a half ago, the circumstances are now ideal for the maintenance of a data repository for all the purposes described above,
supported by the clinical users and resourced for national benchmarking as a routine part of RRT management.

**A:3 Statement of intent**

The Renal Registry provides a focus for the collection and analysis of standardised data relating to the incidence, clinical management and outcome of renal disease. Data will be accepted quarterly according to the Renal Registry Data Set Specification (RRDSS) by automatic downloading from renal centre databases. There will be a core data set, with optional elements of special interest which may be entered by agreement for defined periods. A Report will be published annually to allow comparative audit of facilities, patient demographics, quality of care and outcome measures. Participation is voluntary but the expectation is that all UK renal and transplant units will take advantage of the database by their involvement ultimately. There will be an early concentration on RRT, including transplantation, with an extension to other nephrological activity at a later date. The Registry will provide an independent source of data and analysis on national activity in renal disease.

**A:4 Relationships of the Renal Registry**

4.1 The Registry is a registered Charity through the Renal Association (No. 800733). It was established by a sub-committee of the Renal Association, with additional representation from the British Transplantation Society (BTS) the British Association for Paediatric Nephrology (BAPN), and the Scottish Renal Registry. There is cross representation with the Renal Association Standards and Clinical Trials Committees. The Registry has a Chairman and Secretary nominated by the Renal Association. The Registry has an observer from the Department of Health, and participants from the National Federation of Kidney Patients Associations and Health Care Commissioners.

4.2 It is anticipated that there will be a need for the development of a number of sub-committees as the database and participation enlarges, particularly for data analysis and interpretation.

4.3 The Scottish Renal Registry sends data to the Renal Registry for joint reporting and comparison.

4.4 It is anticipated that the return of English, Welsh and Northern Irish data to the EDTA Registry will be through the Renal Registry. The Scottish Renal Registry already sends data to EDTA.

4.5 A paediatric database has been developed in collaboration with the Renal Registry, and the two databases are compatible. Data from paediatric renal units will be entered on the database, which will allow long-term studies of renal cohorts over a wide range of age.

4.6 The basis of participation for Renal Units nationally will be an Agreement to accept the Renal Registry Data Set Specification for the transmission and retention of data. This will consist of a core data set of some 200 items and further optional elements, which will be returned on a special understanding with the unit for a defined period of reporting. The Agreement will specify the conditions of participation and guarantee Unit anonymity until there is general agreement to disclosure of Unit identity. The responsibilities of the Unit and Registry are clarified in the clauses of the Agreement, as well as the conditions of publication of data. The recent Data Protection Act may have implications for the Registry (5), but the Department of Health has indicated that Registry activity may continue in its present form pending further discussion and clarification of the act.

**A:5 The role of the Registry for nephrologists**

5.1 The clinical community have become increasingly aware of the need to define and understand their activities, particularly in relation to national standards and other renal units.

5.2 The Registry is run by a sub-committee of the Renal Association and therefore by colleagues with similar concerns and experience.

5.3 The Renal Standards documents are designed to give a basis for unit structure and performance, as well as patient-based elements such as case-mix and outcomes. It is anticipated that Standards will become
increasingly based on research evidence and the Cochrane Collaboration has resourced reviews of renal topics recently, which will support the conversion from clinical anecdote.

5.4 The registry data will be available to allow comparative review of many elements of renal unit practice. Data will be anonymised and presented to allow a contrast of individual unit activity and results against national aggregated data.

5.5 Reports of demographic and treatment variables will be available to the participating centres for distribution to Trust, Health Authorities and Regional Offices as required and agreed with the Unit. Reports should facilitate discussion between clinicians, Trust officers and Commissioners.

5.6 Customised data reports can be made available by agreement with the Registry sub-committee. A donation to cover any costs incurred will be requested.

5.7 The Registry committee will welcome suggestions for topics of national audit or research which colleagues feel are of sufficient widespread interest for the Registry to undertake.

5.8 The database has been designed to provide research database facilities for future participation in national and international trials. Members of the Renal Association and other interested parties are welcome to apply to the Registry sub-committee to conduct local or national audit and research using the database. All such projects will need the agreement of the Registry sub-committee, and any costs involved must be met by the applicants.

5.9 These facilities will only be sustainable through co-operation between nephrologists and the Registry. There is a need for high quality and comprehensive data entry at source. Attention will be necessary to the conditions listed in formal Agreements with the Registry.

A:6 The role of the Registry for Trust Managers

6.1 As the basis of the Clinical Governance initiative, the gathering and registration of data relating to patient management is regarded as an essential part of routine patient management in the health service.

6.2 One of the principles of health service informatics is that the best data are acquired from clinical information recorded at the point of health care delivery.

6.3 Renal Services data entered on local systems by staff directly engaged with patients is likely to be of the highest quality, and it is this that the Registry intends to capture.

6.4 The Registry will provide a cost-effective source of detailed information on renal services.

6.5 The regular reports of the Registry will supply the details of patient demographics, treatment numbers and changes, treatment quality and outcomes. Data will be compared with national standards and national performance for benchmarking and quality assurance. The assessment of contract activity and service delivery will be possible through the data returns without the need for further, costly Trust or commissioner administrative activity. These data should be particularly valuable to Contracts Managers and those responsible for Clinical Governance.

6.6 Data will be available on Unit case mix, infrastructure and facilities.

6.7 It is anticipated that data on patients with renal disease other than those requiring RRT will become available in time.

6.8 It is anticipated that Trust interests will ultimately be served by the participation of a national trust representative in the management body of the Registry as Registry activity expands.
A:7 The role of the Registry for Commissioners of health care

7.1 The Commissioners of health care are taken to include Regional Specialty Commissioning Groups and those supporting them, Primary Care Groups (PCGs) and Health Authorities.

7.2 The use of information sources such as the Registry is advised in the National Renal Review so as to promote benchmarking and quality assurance on renal programmes. The comprehensive tracking of relatively small but costly renal cohorts should be regarded as a routine part of case management.

7.3 The Registry will be able to provide validated, comparative reports of renal unit activity on a regular basis to participating centres. These will allow assessment of unit performance in a wide range of variables relating to 'Structure, Process and Outcome' measures.

7.4 There are economies of scale in the performance of audit through the Registry, since multiple local audits will no longer be required.

7.5 The incidence of ESRF treated locally will be apparent from new patient registrations. Mortality and renal transplant rates should also be of interest. The geographical origin of ESRF cases will be indicated by postcode data, which allows the assessment of referral and treatment patterns. This information will allow the expression of geographical and ethnic variations. These data will indicate unmet need in the population and permit judgements of the equity of service provision. The future Registry database should give information on nephrology and pre-dialysis patients, which will allow prediction of the need for ESRF facilities.

7.6 Registry data will be used to track patient acceptance and prevalence rates over time, which will allow the modelling of future demand and validation of predictions.

7.7 Information on the clinical diagnosis of new and existing RRT patients will point to areas where possible preventive measures will have maximal impact.

7.8 The results of higher acceptance rates in the elderly and the consequences of increasing demand from ethnic groups bearing a high prevalence of renal, circulatory and diabetic disease will be measurable.

7.9 Comparative data will be available in all categories for national and regional benchmarking.

7.10 The Registry offers independent expertise in the analysis of Renal Services data and their interpretation, a resource that is widely required but difficult to obtain.

7.11 The cost of supporting the Registry is estimated at between £10 and £15 per registered patient per annum, which is less than 0.05% of the typical cost of a dialysis patient per annum. It is expected that the costs will need to be explicit in renal services contracts so as to ensure the continuation of the Registry on a sound basis.

7.12 The Registry sub-committee now includes a representative of health care commissioners, which allows an influence on the development of the Registry and the topics of interest in data collection and analysis.

A:8 The role of the Registry for national quality assurance agencies

8.1 The role of the Registry in national QA as developed through NICE and CHImp will depend on decisions as to the roles of those agencies (6).

8.2 The demographic, diagnostic and outcomes data could support the investigation of clinical effectiveness in a variety of ways, depending on the focus of interest.

8.3 There may be pressure from some quarters to publish reports in which renal units are clearly identified. The maintenance of Unit anonymity is likely to be important to some, and it may compromise cooperation significantly if abrogated without agreement. Ultimately it is possible that a decision could be forced on the
Registry from outside, although it is hoped this situation will not arise. Consideration of this issue in particular would be welcome in nephrological circles, with correspondence to the Registry Sub-Committee.

A:9 The role of the Registry for patients

The ultimate aim of the Registry is to improve care for patients with renal disease. Appropriate use of the registry information should improve equity of access to care, adequacy of facilities, availability of important but high cost therapies such as erythropoietin, and appropriate and efficient use of resources. The continuing comparative audit of the quality of care should facilitate improvement of care and outcomes of care. It is intended to identify and publish examples of good practice. In these ways patients will be the ultimate beneficiaries of the exercise.

A:10 Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARF</td>
<td>Acute Renal Failure</td>
</tr>
<tr>
<td>BAPN</td>
<td>British Association of Paediatric Nephrology</td>
</tr>
<tr>
<td>BTS</td>
<td>British Transplantation Society</td>
</tr>
<tr>
<td>CCL</td>
<td>Clinical Computing Limited</td>
</tr>
<tr>
<td>CHImp</td>
<td>Commission for Health Improvement</td>
</tr>
<tr>
<td>EDTA</td>
<td>European Dialysis and Transplant Association</td>
</tr>
<tr>
<td>ERA</td>
<td>European Renal Association</td>
</tr>
<tr>
<td>ESRF</td>
<td>End Stage Renal Failure</td>
</tr>
<tr>
<td>HCFA</td>
<td>USA Health Care Finance Administration</td>
</tr>
<tr>
<td>NFKPA</td>
<td>National Federation of Kidney Patients’ Associations</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute of Clinical Excellence</td>
</tr>
<tr>
<td>PCG</td>
<td>Primary Care Group</td>
</tr>
<tr>
<td>RRDSS</td>
<td>Renal Registry Data Set Specification</td>
</tr>
<tr>
<td>RRT</td>
<td>Renal Replacement Therapy</td>
</tr>
<tr>
<td>UKTSSA</td>
<td>United Kingdom Transplant Support Service Authority</td>
</tr>
<tr>
<td>USRDS</td>
<td>United States Renal Data System</td>
</tr>
</tbody>
</table>

A:11 References